During the last session, Immunome Inc (NASDAQ:IMNM)’s traded shares were 0.53 million, with the beta value of the company hitting 1.87. At the end of the trading day, the stock’s price was $9.95, reflecting an intraday loss of -2.64% or -$0.27. The 52-week high for the IMNM share is $30.96, that puts it down -211.16 from that peak though still a striking 9.85% gain since the share price plummeted to a 52-week low of $8.97. The company’s market capitalization is $621.05M, and the average intraday trading volume over the past 10 days was 0.77 million shares, and the average trade volume was 822.29K shares over the past three months.
Immunome Inc (IMNM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IMNM has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.61.
Immunome Inc (NASDAQ:IMNM) trade information
Immunome Inc (IMNM) registered a -2.64% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.64% in intraday trading to $9.95, hitting a weekly high. The stock’s 5-day price performance is 0.91%, and it has moved by -9.30% in 30 days. Based on these gigs, the overall price performance for the year is -33.62%. The short interest in Immunome Inc (NASDAQ:IMNM) is 9.87 million shares and it means that shorts have 11.4 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 56.74% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $23 and $23 respectively. As a result, IMNM is trading at a discount of -131.16% off the target high and -131.16% off the low.
Immunome Inc (IMNM) estimates and forecasts
Statistics show that Immunome Inc has underperformed its competitors in share price, compared to the industry in which it operates. Immunome Inc (IMNM) shares have gone down -34.41% during the last six months, with a year-to-date growth rate less than the industry average at -242.75% against 16.50. In the rating firms’ projections, revenue will decrease -32.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.16M as predicted by 7 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 618.8k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.83M and 1.03M respectively. In this case, analysts expect current quarter sales to shrink by -17.51% and then drop by -39.86% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -48.48%. While earnings are projected to return 17.82% in 2025, the next five years will return 15.77% per annum.
IMNM Dividends
Immunome Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Immunome Inc insiders own 16.99% of total outstanding shares while institutional holders control 83.21%, with the float percentage being 100.24%. BLACKROCK INC. is the largest shareholder of the company, while 172.0 institutions own stock in it. As of 2024-06-30, the company held over 3.76 million shares (or 36.4624% of all shares), a total value of $45.48 million in shares.
The next largest institutional holding, with 4.89 million shares, is of REDMILE GROUP, LLC’s that is approximately 8.1579% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $59.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of Immunome Inc (IMNM) shares are Price (T.Rowe) Small Cap Stock Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) Small Cap Stock Fund owns about 2.07 shares. This amounts to just over 3.31 percent of the company’s overall shares, with a $20.59 million market value. The same data shows that the other fund manager holds slightly less at 1.64, or about 2.62% of the stock, which is worth about $16.3 million.
